Article Details
Retrieved on: 2021-09-07 07:52:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
There are at least seven bispecific monoclonal antibodies in the race to reach the relapsed or refractory multiple myeloma market. Efficacy and safety class ...
Article found on: www.clinicaltrialsarena.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here